Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ipilimumab · Yervoy, BMS-734016

Monoclonal antibody · Antagonist of CTLA-4 · developed by Bristol Myers Squibb

Approved FDA, Mar 2011

BMY Developer

1 Registered trials

What is Ipilimumab?

Ipilimumab is a monoclonal antibody that binds CTLA-4, a negative regulator of T-cell activity, and blocks its interaction with CD80/CD86. This blockade augments T-cell activation and proliferation, including tumor-infiltrating T-effector cells, and reduces T-regulatory cell function, enhancing anti-tumor immune response.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Yervoy, BMS-734016, MDX-010
Drug type: Monoclonal antibody
Targets: CTLA-4, CD80 (binding partner it blocks), CD86 (binding partner it blocks)
Mechanism: Antagonist of CTLA-4
Pathways: T-cell activation, T-cell proliferation, anti-tumor immune response
Therapy area: Oncology
Developer: Bristol Myers Squibb (BMY)
FDA status: Approved as Yervoy (March 25, 2011), BLA125377 · FDA label
UNII: 6T8C155666

✅ FDA-approved uses

Unresectable or metastatic melanoma
Adjuvant treatment of cutaneous melanoma with pathologic involvement of regional lymph nodes
Advanced renal cell carcinoma
Unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
Unresectable or metastatic hepatocellular carcinoma
Metastatic non-small cell lung cancer
Unresectable malignant pleural mesothelioma

From the indications section of the FDA label (version of Aug 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07293351	Phase 1/2	Advanced Renal Cell Carcinoma (RCC)	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Renal Cell Carcinoma (RCC)

Other drugs acting on CTLA4

Tremelimumab FDA approved Botensilimab Phase 2/3 Cadonilimab Early Phase 1 Firastotug Phase 1 Muzastotug Phase 2 Pembrolizumab/Quavonlimab Phase 1/2 Volrustomig Phase 3 Zalifrelimab Phase 1/2

More from Bristol Myers Squibb

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Ipilimumab

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z